Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS FEATURE

Sonoma Biotherapeutics: rallying the regulators

Will regulatory T cells provide needed therapies against inflammatory and autoimmune disorders?
  1. Michael Eisenstein

    1. Philadelphia, Pennsylvania, USA

    View author publications

    You can also search for this author in PubMed  Google Scholar

Therapeutic applications of T cells have been focused up until now on their role as immunological ‘attack dogs’ that can be trained to seek and destroy foreign invaders or malignant growths. This core concept underlies chimeric antigen receptor (CAR)-T cell therapies that are now delivering curative treatments for some blood cancers. But Sonoma Biotherapeutics is trying to do the opposite—to harness regulatory T (Treg) cells to suppress rather than provoke an immune response, potentially offering safe and durable control for various inflammatory and autoimmune conditions.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41587-021-00008-4

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links